Inflammatory markers and bone health in postmenopausal women: a cross-sectional overview.

Aging Bone health Bone mineral density Chemokines Cytokines Ferritin Inflammatory markers Osteo-immunology Postmenopausal women

Journal

Immunity & ageing : I & A
ISSN: 1742-4933
Titre abrégé: Immun Ageing
Pays: England
ID NLM: 101235427

Informations de publication

Date de publication:
2019
Historique:
received: 19 04 2019
accepted: 28 06 2019
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 25 7 2019
Statut: epublish

Résumé

Cytokines, chemokines, C-reactive proteins (CRP) and ferritin are known inflammatory markers. However, cytokines such as interleukin (IL-1β), (IL-6) and tumour necrosis factor (TNF-α) have been reported to interfere with both the bone resorption and bone formation processes. Similarly, immune cell cytokines are known to contribute to inflammation of the adipose tissue especially with obesity. IL-10 but not IL-33 has been linked to lower ferritin levels and anemia. In this study, we hypothesized that specific cytokine levels in the plasma of women with low bone mineral density (BMD) would be higher than those in the plasma of healthy women due to the actions of elevated levels of pro-inflammatory cytokines in inducing osteoclast formation and differentiation during senescence. Levels of cytokines (IFNα2, IFN-γ, IL-12p70, IL-33) and monocyte chemoattractant protein-1 (MCP-1) were significantly higher in the plasma of the osteoporotic group compared to the osteopenic and/or healthy groups. Meanwhile CRP levels were significantly lower in women with osteoporosis ( High levels of cytokines (IFNα2, IFN-γ, IL-12p70, IL-33) and MCP-1 in apparently healthy postmenopausal women are associated with bone health issues. In addition, an increase in levels of IL-10 and IL-33 may be associated with low ferritin levels in this age group. ANZCTR, ACTRN12617000802303. Registered May 31st, 2017, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373020.

Sections du résumé

BACKGROUND BACKGROUND
Cytokines, chemokines, C-reactive proteins (CRP) and ferritin are known inflammatory markers. However, cytokines such as interleukin (IL-1β), (IL-6) and tumour necrosis factor (TNF-α) have been reported to interfere with both the bone resorption and bone formation processes. Similarly, immune cell cytokines are known to contribute to inflammation of the adipose tissue especially with obesity. IL-10 but not IL-33 has been linked to lower ferritin levels and anemia. In this study, we hypothesized that specific cytokine levels in the plasma of women with low bone mineral density (BMD) would be higher than those in the plasma of healthy women due to the actions of elevated levels of pro-inflammatory cytokines in inducing osteoclast formation and differentiation during senescence.
RESULTS RESULTS
Levels of cytokines (IFNα2, IFN-γ, IL-12p70, IL-33) and monocyte chemoattractant protein-1 (MCP-1) were significantly higher in the plasma of the osteoporotic group compared to the osteopenic and/or healthy groups. Meanwhile CRP levels were significantly lower in women with osteoporosis (
CONCLUSIONS CONCLUSIONS
High levels of cytokines (IFNα2, IFN-γ, IL-12p70, IL-33) and MCP-1 in apparently healthy postmenopausal women are associated with bone health issues. In addition, an increase in levels of IL-10 and IL-33 may be associated with low ferritin levels in this age group.
TRIAL REGISTRATION BACKGROUND
ANZCTR, ACTRN12617000802303. Registered May 31st, 2017, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373020.

Identifiants

DOI: 10.1186/s12979-019-0155-x PMID: 31333751 PMC: PMC6621960
pubmed: 31333751
doi: 10.1186/s12979-019-0155-x
pii: 155
pmc: PMC6621960
doi:

Types de publication

Journal Article

Langues

eng

Pagination

15

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Blood. 2000 Sep 1;96(5):1873-8
pubmed: 10961889
Proc Nutr Soc. 2001 Aug;60(3):349-56
pubmed: 11681809
Bone. 2003 Jan;32(1):1-7
pubmed: 12584029
Bone. 2003 Oct;33(4):721-32
pubmed: 14555278
Arch Gerontol Geriatr. 2005 May-Jun;40(3):299-305
pubmed: 15814163
Immun Ageing. 2005 Nov 04;2:14
pubmed: 16271143
Osteoporos Int. 2006 Dec;17(12):1726-33
pubmed: 16983459
Vitam Horm. 2006;74:443-77
pubmed: 17027526
BMC Cell Biol. 2007 Jan 19;8:4
pubmed: 17239241
J Biol Chem. 2007 Nov 9;282(45):33098-106
pubmed: 17690108
Curr Osteoporos Rep. 2009 Dec;7(4):134-9
pubmed: 19968917
Annu Rev Nutr. 2010 Aug 21;30:105-22
pubmed: 20420524
J Neural Transm (Vienna). 2011 Mar;118(3):315-28
pubmed: 20878427
J Immunol. 1990 Nov 15;145(10):3297-303
pubmed: 2121824
Arthritis Res Ther. 2012 Jan 20;14(1):R14
pubmed: 22264405
J Biol Chem. 2012 May 4;287(19):15728-38
pubmed: 22416138
Mediators Inflamm. 2014;2014:561459
pubmed: 24876674
Arh Hig Rada Toksikol. 2014 Jun;65(2):139-48
pubmed: 24945416
Front Pharmacol. 2014 Jul 16;5:152
pubmed: 25076907
Curr Med Chem. 2015;22(5):596-603
pubmed: 25386817
Osteoporos Int. 2015 Feb;26(2):727-35
pubmed: 25410434
PLoS One. 2015 Mar 17;10(3):e0121971
pubmed: 25781614
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4104-10
pubmed: 26150497
BMC Immunol. 2015 Oct 08;16:60
pubmed: 26449657
Curr Med Chem. 2016;23(33):3754-3774
pubmed: 27604089
J Biol Chem. 2017 Mar 17;292(11):4686-4699
pubmed: 28130449
Int Immunol. 2017 Nov 1;29(9):401-409
pubmed: 28541437
Sci Rep. 2017 Aug 17;7(1):8666
pubmed: 28819125
Calcif Tissue Int. 2018 May;102(5):512-521
pubmed: 29018933
Clin Chem. 2018 Feb;64(2):374-385
pubmed: 29038157
Exp Mol Med. 2017 Nov 3;49(11):e388
pubmed: 29099095
Immune Netw. 2018 Feb 07;18(1):e8
pubmed: 29503739
Osteoporos Int. 2018 Jul;29(7):1581-1589
pubmed: 29808230
Int J Mol Sci. 2018 Jul 16;19(7):null
pubmed: 30013010
Biores Open Access. 2018 Oct 10;7(1):150-158
pubmed: 30327744
Sci Rep. 2019 Mar 7;9(1):3786
pubmed: 30846811
J Am Geriatr Soc. 1995 Mar;43(3):236-9
pubmed: 7884109
J Bone Miner Res. 1994 Aug;9(8):1313-8
pubmed: 7976512
J Bone Miner Res. 1993 Jan;8(1):51-9
pubmed: 8427049
Clin Sci (Lond). 1996 Aug;91(2):121-30
pubmed: 8795434
Maturitas. 1997 Jan;26(1):63-71
pubmed: 9032749
Clin Rheumatol. 1997 Mar;16(2):162-5
pubmed: 9093798
Eur J Clin Invest. 1998 Jul;28(7):520-7
pubmed: 9726030

Auteurs

Bolaji Lilian Ilesanmi-Oyelere (BL)

1Department of Nutritional Science, School of Food and Advanced Technology, College of Sciences, Massey University, Tennent Drive, Palmerston North, 4442 New Zealand.
2Riddet Institute, Palmerston North, 4442 New Zealand.
3Food Nutrition & Health Team, AgResearch Grasslands, Palmerston North, 4442 New Zealand.
ORCID: 0000-0003-2274-4206

Linda Schollum (L)

Fonterra Research and Development Centre, Palmerston North, 4472 New Zealand.

Barbara Kuhn-Sherlock (B)

BKS Consulting, Hamilton, New Zealand.

Michelle McConnell (M)

6Department of Microbiology and Immunology, University of Otago, Dunedin, 9054 New Zealand.

Sonya Mros (S)

6Department of Microbiology and Immunology, University of Otago, Dunedin, 9054 New Zealand.

Jane Coad (J)

1Department of Nutritional Science, School of Food and Advanced Technology, College of Sciences, Massey University, Tennent Drive, Palmerston North, 4442 New Zealand.

Nicole C Roy (NC)

2Riddet Institute, Palmerston North, 4442 New Zealand.
3Food Nutrition & Health Team, AgResearch Grasslands, Palmerston North, 4442 New Zealand.
High-Value Nutrition National Science Challenge, Auckland, New Zealand.

Marlena Cathorina Kruger (MC)

1Department of Nutritional Science, School of Food and Advanced Technology, College of Sciences, Massey University, Tennent Drive, Palmerston North, 4442 New Zealand.
2Riddet Institute, Palmerston North, 4442 New Zealand.
8School of Health Sciences, College of Health, Massey University, Palmerston North, 4442 New Zealand.

Classifications MeSH